Dec 15, 2022
Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Dec 07, 2022
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
Nov 23, 2022
Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual Meeting
Oct 28, 2022
Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib
Oct 27, 2022
Pharming Group reports earnings for the first nine months of 2022
Oct 11, 2022
Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib
Sep 28, 2022
Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib
Sep 07, 2022
CEO of Pharming to present at H.C. Wainwright 24th Annual Global Investment Conference
Aug 04, 2022
Pharming Group reports financial results for the first half of 2022
Aug 02, 2022
Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency
Displaying 1 - 10 of 20